{
  "abstract": "Injectable long-acting cabotegravir plus rilpivirine (CAB+RPV LA) is an effective treatment option for people living with HIV. Unlike regimens containing tenofovir with lamivudine (3TC) or emtricitabine (FTC), it lacks therapeutic activity against the hepatitis B virus, and hepatitis B vaccination is recommended for non-immune individuals. We present a case of acute hepatitis B after switching to CAB+RPV LA in a previously vaccinated individual.",
  "authors": [
    {
      "affiliations": [
        "Infectious Diseases Unit, Ospedale Alessandro Manzoni, Lecco, Italy"
      ],
      "name": "Valentina Morena"
    },
    {
      "affiliations": [
        "Infectious Diseases Unit, Ospedale Alessandro Manzoni, Lecco, Italy"
      ],
      "name": "Nicole Gemignani"
    },
    {
      "affiliations": [
        "Infectious Diseases Unit, Ospedale Alessandro Manzoni, Lecco, Italy"
      ],
      "name": "Martina Bottanelli"
    },
    {
      "affiliations": [
        "Infectious Diseases Unit, Ospedale Alessandro Manzoni, Lecco, Italy"
      ],
      "name": "Federico Conti"
    },
    {
      "affiliations": [
        "Infectious Diseases Unit, Ospedale Alessandro Manzoni, Lecco, Italy"
      ],
      "name": "Chiara Molteni"
    },
    {
      "affiliations": [
        "Infectious Diseases Unit, Ospedale Alessandro Manzoni, Lecco, Italy"
      ],
      "name": "Giada Valesecchi"
    },
    {
      "affiliations": [
        "Infectious Diseases Unit, Ospedale Alessandro Manzoni, Lecco, Italy"
      ],
      "name": "Silvia Pontiggia"
    },
    {
      "affiliations": [
        "Infectious Diseases Unit, Ospedale Alessandro Manzoni, Lecco, Italy"
      ],
      "name": "Stefania Piconi"
    }
  ],
  "title": "Acute hepatitis B following a switch to long-acting cabotegravir plus rilpivirine in an individual with a history of hepatitis B vaccination",
  "uid": "0ed21710-f548-54c3-96d3-0bb7e3989691"
}